164 related articles for article (PubMed ID: 38492861)
1. STING-activating cyclic dinucleotide-manganese nanoparticles evoke robust immunity against acute myeloid leukemia.
Aikins ME; Sun X; Dobson H; Zhou X; Xu Y; Lei YL; Moon JJ
J Control Release; 2024 Apr; 368():768-779. PubMed ID: 38492861
[TBL] [Abstract][Full Text] [Related]
2. The stimulator of interferon genes (STING) agonists for treating acute myeloid leukemia (AML): current knowledge and future outlook.
Song X; Peng Y; Wang X; Chen Q; Lan X; Shi F
Clin Transl Oncol; 2023 Jun; 25(6):1545-1553. PubMed ID: 36587109
[TBL] [Abstract][Full Text] [Related]
3. Amplifying STING activation by bioinspired nanomedicine for targeted chemo- and immunotherapy of acute myeloid leukemia.
Wang X; Huang R; Wu W; Xiong J; Wen Q; Zeng Y; Chen T; Li J; Zhang C; Zhong JF; Yang S; Zhang X
Acta Biomater; 2023 Feb; 157():381-394. PubMed ID: 36375786
[TBL] [Abstract][Full Text] [Related]
4. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy.
Lv M; Chen M; Zhang R; Zhang W; Wang C; Zhang Y; Wei X; Guan Y; Liu J; Feng K; Jing M; Wang X; Liu YC; Mei Q; Han W; Jiang Z
Cell Res; 2020 Nov; 30(11):966-979. PubMed ID: 32839553
[TBL] [Abstract][Full Text] [Related]
5. STING Pathway Activation Stimulates Potent Immunity against Acute Myeloid Leukemia.
Curran E; Chen X; Corrales L; Kline DE; Dubensky TW; Duttagupta P; Kortylewski M; Kline J
Cell Rep; 2016 Jun; 15(11):2357-66. PubMed ID: 27264175
[TBL] [Abstract][Full Text] [Related]
6. Amplifying STING activation by cyclic dinucleotide-manganese particles for local and systemic cancer metalloimmunotherapy.
Sun X; Zhang Y; Li J; Park KS; Han K; Zhou X; Xu Y; Nam J; Xu J; Shi X; Wei L; Lei YL; Moon JJ
Nat Nanotechnol; 2021 Nov; 16(11):1260-1270. PubMed ID: 34594005
[TBL] [Abstract][Full Text] [Related]
7. Manganese-Based Nanoactivator Optimizes Cancer Immunotherapy
Hou L; Tian C; Yan Y; Zhang L; Zhang H; Zhang Z
ACS Nano; 2020 Apr; 14(4):3927-3940. PubMed ID: 32298077
[TBL] [Abstract][Full Text] [Related]
8. Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers.
Yi M; Niu M; Zhang J; Li S; Zhu S; Yan Y; Li N; Zhou P; Chu Q; Wu K
J Hematol Oncol; 2021 Sep; 14(1):146. PubMed ID: 34526097
[TBL] [Abstract][Full Text] [Related]
9. SHR1032, a novel STING agonist, stimulates anti-tumor immunity and directly induces AML apoptosis.
Song C; Liu D; Liu S; Li D; Horecny I; Zhang X; Li P; Chen L; Miller M; Chowdhury R; Issa M; Shen R; Yan Y; Zhang F; Zhang L; Zhang L; Bai C; Feng J; Zhuang L; Zhang R; Li J; Wilkinson H; Liu J; Tao W
Sci Rep; 2022 May; 12(1):8579. PubMed ID: 35595822
[TBL] [Abstract][Full Text] [Related]
10. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
[TBL] [Abstract][Full Text] [Related]
11. STING agonist-loaded mesoporous manganese-silica nanoparticles for vaccine applications.
Xu C; Dobson HE; Yu M; Gong W; Sun X; Park KS; Kennedy A; Zhou X; Xu J; Xu Y; Tai AW; Lei YL; Moon JJ
J Control Release; 2023 May; 357():84-93. PubMed ID: 36948420
[TBL] [Abstract][Full Text] [Related]
12. Immune-Based Therapeutic Interventions for Acute Myeloid Leukemia.
Perna F; Espinoza-Gutarra MR; Bombaci G; Farag SS; Schwartz JE
Cancer Treat Res; 2022; 183():225-254. PubMed ID: 35551662
[TBL] [Abstract][Full Text] [Related]
13. A manganese-phenolic network platform amplifying STING activation to potentiate MRI guided cancer chemo-/chemodynamic/immune therapy.
Pang X; Fu C; Chen J; Su M; Wei R; Wang Y; Lin W; Wei X; Jiang X; Yang X; Yang H; Wang J; Yang R
Biomater Sci; 2023 May; 11(11):3840-3850. PubMed ID: 37074080
[TBL] [Abstract][Full Text] [Related]
14. Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML.
Masarova L; Kantarjian H; Garcia-Mannero G; Ravandi F; Sharma P; Daver N
Adv Exp Med Biol; 2017; 995():73-95. PubMed ID: 28321813
[TBL] [Abstract][Full Text] [Related]
15. Overcoming resistance to STING agonist therapy to incite durable protective antitumor immunity.
Lemos H; Ou R; McCardle C; Lin Y; Calver J; Minett J; Chadli A; Huang L; Mellor AL
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32847988
[TBL] [Abstract][Full Text] [Related]
16. Insight into the dichotomous regulation of STING activation in immunotherapy.
Hu Z; Yang Y; Fang L; Zhou J; Zhang H
Immunopharmacol Immunotoxicol; 2021 Apr; 43(2):126-137. PubMed ID: 33618600
[TBL] [Abstract][Full Text] [Related]
17. Acute myeloid leukemia cell membrane-coated nanoparticles for cancer vaccination immunotherapy.
Johnson DT; Zhou J; Kroll AV; Fang RH; Yan M; Xiao C; Chen X; Kline J; Zhang L; Zhang DE
Leukemia; 2022 Apr; 36(4):994-1005. PubMed ID: 34845316
[TBL] [Abstract][Full Text] [Related]
18. Emerging mechanisms and implications of cGAS-STING signaling in cancer immunotherapy strategies.
Zhang J; Yu S; Peng Q; Wang P; Fang L
Cancer Biol Med; 2024 Jan; 21(1):45-64. PubMed ID: 38172538
[TBL] [Abstract][Full Text] [Related]
19. Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy.
Shae D; Becker KW; Christov P; Yun DS; Lytton-Jean AKR; Sevimli S; Ascano M; Kelley M; Johnson DB; Balko JM; Wilson JT
Nat Nanotechnol; 2019 Mar; 14(3):269-278. PubMed ID: 30664751
[TBL] [Abstract][Full Text] [Related]
20. Multifunctional STING-Activating Mn
Zhou M; Wang X; Lin S; Cheng Y; Zhao S; Lin J; Fang Z; Lou Z; Qin L; Wei H
Adv Healthc Mater; 2020 Jul; 9(13):e2000064. PubMed ID: 32484320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
